Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene
- 1 November 1986
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 140 (3), 901-907
- https://doi.org/10.1016/0006-291x(86)90720-5
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Mitoxantrone: A New Anticancer Drug with Significant Clinical ActivityAnnals of Internal Medicine, 1986
- Mitoxanthrone and bisantrene inhibition of platelet aggregation and prostaglandin E2 production in vitroBiochemical Pharmacology, 1985
- Induction of Neovascularization and Nonlymphoid Mesenchymal Cell Proliferation by Macrophage Cell LinesJournal of Leukocyte Biology, 1985
- Tumor AngiogenesisAdvances in Cancer Research, 1985
- Mitoxantrone (novantrone): a review of experimental and early clinical studiesCancer Treatment Reviews, 1983
- Prostaglandin E and cancer GrowthCancer Immunology, Immunotherapy, 1980
- Neovasculogenesis. Triggering factors and possible mechanismsSurvey of Ophthalmology, 1979
- Neovasculogenic Ability of Prostaglandins, Growth Factors, and Synthetic ChemoattractantsAmerican Journal of Ophthalmology, 1978
- Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinonesJournal of Medicinal Chemistry, 1978
- Polymers for the sustained release of proteins and other macromoleculesNature, 1976